Severe acute respiratory syndrome: identification of the etiological agent.

acute respiratory syndrome. New Engl. J. Med. 348, 1953–1966 3 Drosten, C. et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New Engl. J. Med. 348, 1967–1976 4 Peiris, J.S.M. et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319–1325 5 Ruan, Y.J. et al. (2003) Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 361, 1779–1785 6 Rota, P.A. et al. (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399 7 Marra, M.A. et al. (2003) The genome sequence of the SARS-associated coronavirus. Science 300, 1399–1404 8 Anand, K. et al. (2003) Coronavirus main proteinase (3CL) structure: basis for design of anti-SARS drugs. Science 300, 1763–1767 9 Philips, J.J. et al. (2002) Murine coronavirus spike glycoprotein medicates degree of viral spread, inflammation and virus-induced immunopathology in the central nervous system. Virology 301, 109–120 10 Gallagher, T.M. and Buchmeier, M.J. (2001) Coronavirus spike proteins in viral entry and pathogenesis. Virology 279, 371–374 11 Tsai, J.C. et al. (2003) The N-terminal domain of the murine coronavirus spike glycoprotein determines the CEACAM1 receptor specificity of the virus strain. J. Virol. 77, 841–850 12 Bonavia, A. et al. (2003) Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. J. Virol. 77, 2530–2538 13 Peiris, J.S.M. et al. (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772 14 Kilby, J.M. et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302–1307